Results 21 to 30 of about 262 (144)

甲状腺自身抗体定量检测的临床应用

open access: yesZhongguo shiyan zhenduanxue, 2010
目的探讨血清中3种甲状腺自身抗体定量检测,在甲状腺疾病诊治中的价值。方法收集2009-2010年于我院门诊就诊及住院的甲状腺疾病患者238例,通过患者的病史、症状、体征及相关的辅助检查将患者分组。分别检测患病组及正常对照组血清中TPOAb、TGAb、TRAb浓度,观察3个抗体水平在不同疾病中的变化情况。结果不同疾病组及正常对照组血清中TPOAb、TGAb浓度水平差异具有统计学意义,其中桥本病、Graves’病组,血清中两种抗体水平与其他各组比较差异具有统计学意义 ...
王旭, 张会英
doaj  

Identifying potentially suitable and accessible refugia to mitigate impacts of an emerging disease on a rare tree

open access: yesConservation Biology, Volume 39, Issue 6, December 2025.
Abstract Identifying refugia from emerging threats is vital to ensure the persistence of rare and threatened species, but modeling habitat distribution for these species is challenging and the role of people in refuge management is rarely considered. Myrtle rust is an emerging infectious disease that represents a grave threat to the rare wetland tree ...
Sarah M. Herbert   +7 more
wiley   +1 more source

甲状腺自身抗体联合检测在Graves病和桥本氏甲状腺炎中的诊断意义

open access: yesZhongguo shiyan zhenduanxue, 2010
目的探讨抗甲状腺球蛋白抗体(TGAb)、甲状腺过氧化物酶抗体(TPOAb)和促甲状腺激素受体抗体(TRAb)在Graves病和桥本氏甲状腺炎中的诊断意义。方法对我院在2006-2009年收治的264例Graves病患者和86例桥本氏甲状腺炎患者,分别检测血中TGAb,TPOAb和TRAb的含量,观察两组间的差异,并对264例Graves病患者根据病情分为初治组、治疗组和缓解组,同样检测血中以上3种抗体,观察其在病程中的动态变化。结果 TRAb在Graves病患者中阳性率较高,并随病情的缓解,浓度逐渐下降,
徐冬岩, 于波, 刘锐
doaj  

Effect of Gabapentin Administered With Prednisolone, Ciclosporin or a Placebo on Clinical Outcomes and Motor Activity in Cats With Atopic Skin Syndrome: A Prospective, Blinded, Placebo‐Controlled Study

open access: yesVeterinary Dermatology, Volume 36, Issue 6, Page 814-824, December 2025.
Background: Gabapentin reportedly decreases central sensitisation, a disorder associated with chronic pruritus in humans, although this is not well documented in cats. Its combined use with the standard antipruritic therapy for feline atopic skin syndrome (FASS) is not yet described.
Jeanne Morency   +10 more
wiley   +1 more source

TRAb的动态监测在Graves病中的临床意义

open access: yesZhongguo shiyan zhenduanxue, 2016
Graves病又称弥漫性毒性甲状腺肿(GD),为病因尚未明确的自身免疫性甲状腺疾病。甲亢期无痛性亚甲炎多以甲状腺毒症为突出表现,临床上容易被误诊为Graves病。但两者有完全不同的治疗方案,因此临床医生需要准确的鉴别两种疾病。TRAb是自身免疫性甲状腺疾病患者体内产生的一种自身抗体,大量医学研究已经证明TRAb在Graves病的发生、发展及转归中起着关键作用 ...
张晓丽, 刘馨悦, 刘波
doaj  

World Association for Veterinary Dermatology Consensus Statement for Diagnosis, and Evidence‐Based Clinical Practice Guidelines for Treatment and Prevention of Canine Leishmaniosis

open access: yesVeterinary Dermatology, Volume 36, Issue 6, Page 723-787, December 2025.
Hyperkeratosis of (a) the footpads and (b) the nasal planum. ABSTRACT Background Canine leishmaniosis (CanL) due to Leishmania infantum remains common, and veterinarians do not always follow scientifically sound approaches for diagnosis, treatment and prevention. Objectives To provide consensus guidelines for diagnosis and evidence‐based guidelines for
Manolis N. Saridomichelakis   +9 more
wiley   +1 more source

Efficacy and Field Safety of Ilunocitinib for the Control of Allergic Dermatitis in Client‐Owned Dogs: A Multicenter, Double‐Masked, Randomised, Placebo‐Controlled Clinical Trial

open access: yesVeterinary Dermatology, Volume 36, Issue 6, Page 825-837, December 2025.
Background: Inhibition of the Janus kinase pathway is an established treatment for allergic dermatitis. Objective: To evaluate the efficacy and safety of ilunocitinib for control of pruritus in dogs with allergic dermatitis in a randomised, double‐masked clinical trial.
Sophie Forster   +5 more
wiley   +1 more source

介入栓塞治疗难治性Graves 病的临床应用与病理机制

open access: yesZhongshan Daxue xuebao. Yixue kexue ban, 2000
【目的】观察介入栓塞治疗难治性Graves 病的临床疗效及甲状腺病理形态变化, 探讨其病理机制, 为临床提供治 疗依据及应用经验。【方法】采用Seldinger 技术, 选择性插管至甲状腺动脉, 注入栓塞剂治疗20 例难治性Graves 病, 并观察 伴巨大甲状腺、经栓塞后行手术治疗者的甲状腺病理形态变化。【结果】①6 例栓塞2 ~ 3 周后行双侧甲状腺次全切, 手术顺 利, 临床治愈;未有手术的14 例, 除2 例尚需分别用他巴唑(tapazole)5~ 10 mg/ d 或丙硫氧嘧啶(PTU ...
肖海鹏
doaj  

Efficacy and field safety of ilunocitinib for the control of atopic dermatitis in client‐owned dogs: A multicentre, double‐masked, randomised, placebo‐controlled clinical trial

open access: yesVeterinary Dermatology, Volume 36, Issue 5, Page 647-659, October 2025.
Background – Inhibition of the Janus kinase (JAK) pathway is a well‐established option for canine atopic dermatitis (cAD). Objective – To evaluate the efficacy and safety of ilunocitinib, a novel JAK inhibitor for the control of pruritus and skin lesions in client‐owned dogs with cAD.
Sophie Forster   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy